# Clinical Trials Data EGFR - Document 51

# Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

## Clinical Trial: https://clinicaltrials.gov/study/NCT02001896

"eligibilityCriteria": "Inclusion Criteria:\n\n\* adult patients, \\>=18 years of age;advanced (stage IIIB/IV)non-small cell lung cancer;measurable disease;ECOG Performance Status 0-2.\n\nExclusion Criteria:\n\n\* prior exposure to agents directed at the HER axis;prior chemotherapy or systemic anti-tumor therapy after advanced disease;unstable systemic disease; any other malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of cervix.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't state whether having an EGFR mutation is an inclusion or exclusion criteria. Therefore, we cannot definitively say whether a patient with an EGFR mutation would be eligible. The criteria focus on stage, prior treatments, and general health status. EGFR mutation status is crucial for determining eligibility for targeted therapies in lung cancer, so it's likely relevant. \*\*More information is needed about the trial's specific requirements regarding EGFR mutations to determine eligibility.\*\*